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1. Introduction
The major disease epidemics of modern society are not those of contagion, but are the result
of lifestyle imposed upon our genetic pre-disposition. Unrestricted access to calorie-dense
food, along with a reduction in physical activity, has resulted in a rapid rise in metabolic
disorders. One such condition, type 2 diabetes (T2D), has increased dramatically in recent
times, with the International Diabetes Foundation estimating that 371 million people world‐
wide have T2D, with this number expected to increase to greater than 550 million by 2030
(http://www.idf.org/diabetesatlas/5e/Update2012). T2D is characterized by fasting blood
glucose levels higher than 7.0 mM or two-hour blood glucose levels higher than 11.1 mM after
a glucose tolerance test. T2D rarely occurs in isolation and is frequently associated with a
number of comorbidities, including obesity, dyslipidemia, cardiovascular disease, and
inflammation, collectively referred to as the metabolic syndrome.
A central aspect of the disorders comprising the metabolic syndrome is insulin resistance;
defined as an impaired ability for insulin to regulate fuel metabolism in target tissues. With
respect to glucose homeostasis the main insulin-responsive tissues involved are skeletal
muscle, liver and adipose tissue. Under normal physiological conditions, insulin is released
into the circulation from the beta cells in the islets of Langerhans in the pancreas in response
to the ingestion of a meal. Upon binding to its receptor, insulin stimulates a well-described
signaling cascade [1] involving the phosphorylation, docking and translocation of a series of
signaling molecules, ultimately leading to alterations in specific endpoints of glucose and lipid
metabolism (Figure 1):
• In skeletal muscle, insulin promotes the translocation of the glucose transporter GLUT4 to
the plasma membrane to increase glucose uptake and also stimulates glycogen synthesis.
• The major hepatic actions of insulin are the promotion of glycogen and lipid synthesis and
the suppression of gluconeogenesis.
© 2013 Turner; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
• In adipose tissue, insulin stimulates GLUT4-mediated glucose uptake and lipid synthesis,
and additionally represses lipolysis, leading to net lipid accumulation.
IRS, insulin receptor substrate; SHC, Src Homology 2 domain; GRB2, growth factor receptor-bound protein 2; ERK, ex‐
tracellular-signal-regulated kinases or classical MAP kinases; PI3K Phosphoinositide 3-kinase; PDK1, phosphoinositide-
dependent protein kinase 1; mTORC mammalian target of rapamycin complex; FoxO1 Forkhead box protein O1;
SREBP1c sterol regulatory element binding protein 1c; GSK-3, glycogen synthase kinase 3; AS160, 160 kDa Akt sub‐
strate.
Figure 1. Insulin signaling pathway. Binding of insulin to the insulin receptor initiates a signaling cascade that involves
multiple phosphorylation events (green circles) and leads to alterations in glucose and lipid metabolism.
In the insulin resistant state, the effect of insulin on the above pathways is compromised,
leading to insufficient uptake of glucose into tissues and an impaired suppression of hepatic
glucose output. To overcome the diminished effectiveness of insulin, the pancreatic beta cells
secrete more insulin. The ensuing hyperinsulinemia can adequately compensate for the insulin
resistance in most of the population, however in genetically susceptible individuals, the beta
cells ultimately fail in the face of the increased workload and this leads to elevated blood
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glucose levels and T2D. Thus insulin resistance can be considered a very early and important
player in the pathogenesis of T2D.
At the molecular level, the precise mechanisms responsible for insulin resistance are not fully
elucidated. Studies have reported overactivation of stress-related and inflammatory pathways
in tissues of insulin resistant humans and rodents. For example, ER stress was shown by the
Hotamisligil lab to be present in the liver of obese mice and subsequent studies using chap‐
erones that reduce ER stress revealed improvements in metabolic homeostatsis [2,3]. Oxidative
stress has also been implicated in the development of insulin resistance, with studies showing
elevated reactive oxygen species generation in insulin resistant cell models, rodents and
humans [4-6]. Finally, inflammation in adipose tissue and liver (and to some extent muscle)
has been reported in obese, insulin-resistant humans and rodents [7,8]. While the above factors
are often described as causative players in the development of insulin resistance, it still remains
unresolved whether they are the primary factors leading to diminished insulin action, or if
they arise as a consequence of insulin resistance.
One factor that is one of the earliest defects associated with insulin resistance and T2D is lipid
accumulation in non-adipose tissues [9-13]. Under conditions of excess nutrient supply, fatty
acids and their metabolites inappropriately spillover into tissues such as skeletal muscle, liver
and the heart, precipitating defects in insulin action. More specifically, while elevated trigly‐
cerides are frequently reported in tissues of insulin resistant humans and rodents, the accu‐
mulation of metabolically active long chain acyl-CoAs (LCACoAs) and other cytosolic lipid
metabolites, such as ceramides and diacylglycerol (DAG), are considered to be more directly
linked with insulin resistance [9,10]. In support of this, the above lipid metabolites can activate
many pathways and factors (e.g. protein kinase C, c-jun N-terminal kinase (JNK), reactive
oxygen species, the nuclear factor κB (NFκB) pathway, protein phosphatase A2 (PPA2) and
cytokines) that directly antagonize insulin signal transduction and glucose metabolism
pathways [9,10].
The extent of lipid accumulation within any given tissue is determined by several factors.
Under conditions of elevated lipid availability, enhanced uptake of fat into tissues contributes
to greater lipid deposition [14,15]. This increased uptake is associated with greater expression
and/or translocation of fatty acid transport proteins (e.g. CD36). Any impairment in the
utilization (oxidation) of lipids would also be predicted to increase partitioning of lipids into
storage pools. Indeed, over the last decade a popular theory has emerged suggesting that
defects in mitochondrial oxidative metabolism, particularly in skeletal muscle, lead to obesity
and lipid accumulation and thus may play an important role in the pathogenesis of insulin
resistance and T2D [16].
2. Mitochondrial structure and function
The mitochondrion is the key site for energy production in cells, providing a platform for the
oxidation of fuel substrates to produce ATP. During the oxidative metabolism of nutrients
(primarily glucose and fatty acids under normal circumstances), reducing equivalents (NADH
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or FADH2) are generated from glycolysis, the TCA cycle and β-oxidation. When NADH and
FADH2 are oxidized to NAD+ or FAD, electrons pass along the mitochondrial electron
transport chain coupled to the pumping of protons into the intermembrane space through
complex I, III and IV. The electrons are transferred to oxygen at complex IV to produce H2O.
The pumped protons generate an electrochemical gradient across the inner mitochondrial
membrane, which is used as the driving force for the ATP synthase (complex V) to produce
ATP. The electrochemical gradient may also dissipate through uncoupling proteins (UCP),
producing heat in a process referred to as thermogenesis.
TAG Triacylglycerol; DAG Diacylglycerol; PDH Pyruvate dehydrogenase; CPT Carnitine palmitoyltransferase; UCP Un‐
coupling Protein
Figure 2. During the oxidative metabolism of glucose and fatty acids, reducing equivalents (NADH or FADH2) are gen‐
erated from glycolysis, the TCA cycle and β-oxidation. When NADH and FADH2 are oxidized to NAD+ or FAD, electrons
pass along the mitochondrial respiratory chain while protons are pumped into the intermembrane space through
complex I, III and IV. The electrons are transferred to oxygen at complex IV to produce H2O. The pumped protons gen‐
erate an electrochemical gradient across the inner mitochondrial membrane, which is used as the driving force for ATP
synthase (complex V) to produce ATP. Protons can also enter the matrix through uncoupling proteins. Deficiencies in
mitochondrial fatty acid oxidation can lead to the buildup of bioactive lipid intermediates (red circle) that can cause
insulin resistance.
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2.1. Mitochondrial biogenesis
Mitochondrial function within a given tissues is regulated at a number of different levels,
including the number or density of mitochondria. The biogenesis of new mitochondria
involves a coordinated interaction between the nuclear and mitochondrial genomes [17]. The
mitochondrial genome encodes for 13 protein subunits of the mitochondrial respiratory
complexes, as well tRNAs and rRNAs necessary for the translation of the mitochondrial-
encoded proteins. The nuclear genome therefore encodes the vast majority of mitochondrial
proteins and also encodes the transcription factor responsible for controlling mitochondrial
transcription, namely TFAM. Proteins encoded by the nucleus are translated in the cytosol and
imported into the appropriate mitochondrial compartments via a suite of import complexes
[18]. Thus it is obvious that mitochondrial biogenesis is an extremely complex process, reliant
upon the exquisite orchestration of separate genomes and multiple cellular processes.
The master regulators of the mitochondrial biogenic program are the peroxisome proliferator-
activated receptor gamma (PPARγ) coactivator (PGC-1) family of transcriptional coactivators.
The PGC-1 proteins are promiscuous coactivators that interact with and promote transcrip‐
tional activity in the key transcription factors (described below) that regulate the expression
of genes involved in mitochondrial substrate oxidation, fibre-type determination, mitochon‐
drial biogenesis and mitochondrial function [17,19]. The PGC-1 proteins do not bind directly
to DNA, but instead recruit a wide array of chromatin-remodelling cofactors to transcriptional
complexes. PGC-1α was the first described member of this family, initially identified in a screen
for activators of PPARγ in brown adipocytes [20]. The other members of the family, PGC-1β
and PRC were identified based on sequence homology to PGC-1α [21,22]. Overexpression and
knockout studies for PGC-1 proteins have provided clear evidence that these coactivator
proteins induce increases in mitochondrial oxidative capacity and promote a switch to a more
oxidative fibre type in muscle [23-27].
PGC-1α appears to be the most responsive member of this family, with PGC-1β proposed to
be important in the regulation of basal mitochondrial content [28]. Environmental stimuli such
as exercise, fasting and cold exposure can induce a rapid increase in PGC-1α expression and
activity [19]. PGC-1α also promotes its own expression through a feed-forward mechanism
[29]. The activity of PGC-1α is regulated by a number of post-translational mechanisms
including acetylation and phosphorylation. The relative level of PGC-1α acetylation is
determined by the balance between the activity of the acetyltransferase GCN5 and the NAD+
dependent deacetylase SIRT1 [30,31]. With respect to phosphorylation, the energy sensing
kinase AMPK has been shown to directly phosphorylate PGC-1α and alter its transcriptional
activity [32]. Thus in responsive to specific stimuli, changes in the concentrations of key
molecules within the intracellular milieu (e.g. NAD+, adenine nucleotides) results in stimula‐
tion of upstream regulators of PGC-1α activity and initiaition of the mitochondrial biogenic
cascade. While the role of PGC-1α in regulating mitochondrial biogenesis is well established,
recent work from the Spiegelman lab has described a novel splice isoform of PGC-1α that also
regulates skeletal muscle hypertrophy [33], indicating there is still much to learn about the
biology of the PGC-1 transcriptional coactivator proteins.
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2.2. Nuclear transcription factors involved in mitochondrial biogenesis
PGC-1 proteins orchestrate the mitochondrial biogenic program by promoting transcriptional
activity through a variety of transcription factors. Nuclear transcription factors bind to specific
sequences in gene promoter regions to regulate transcription of a subset of specific genes. The
key transcription factors that regulate many of the genes involved in the respiratory chain and
other mitochondrial pathways are described below.
2.2.1. Nuclear Respiratory Factor 1 (NRF-1)
NRF-1 plays a crucial role in coordinating nuclear and mitochondrial gene expression. It
induces the expression of TFAM, as well as other components of the mitochondrial transcrip‐
tional machinery (e.g. TFB1M and TFB2M) [34,35]. NRF-1 also promotes the expression of
mitochondrial import proteins that are involved in transporting nuclear-encoded proteins into
mitochondria. Forced overexpression of NRF-1 in skeletal muscle in mice, results in increased
expression of a subset of mitochondrial proteins, but no net increase in mitochondrial oxidative
capacity [36]. Deletion of NRF-1 in mice on the other hand has been shown to be embryonic
lethal, due to disruption of mitochondrial function [37].
2.2.2. Nuclear Respiratory Factor 2 (NRF-2/GABP)
Nuclear respiratory factor-2 (NRF-2 humans/GABP mice) is a second critical transcription
factor that regulates the expression of proteins involved in mitochondrial function and
biogenesis. The target genes of NRF-2 include all respiratory complex IV subunits, TFAM and
a range of other proteins involved in mitochondrial transcription and replication [38]. Con‐
sistent with the findings in NRF-1 knockout animals, NRF-2 deletion also causes a lethal
phenotype, underlying the crucial importance of this transcription factor [39].
2.2.3. Estrogen-Related Receptors (ERR)
The estrogen related receptor family contains 3 members, ERRα, ERRβ, ERRγ. ERRs regulate
the expression of a wide array of genes involved in substrate uptake, the TCA cycle, fatty acid
oxidation (FAO), oxidative phosphorylation and mitochondrial fusion [40,41]. ERRα knockout
mice only display a mild phenotype [42], however deletion of the other two isoforms results
in a lethal phenotype [43,44].
2.2.4. Peroxisome-Proliferator Activated Receptors (PPAR)
Similar to the ERR family, PPARs nuclear receptors that exist as 3 separate isoforms PPARα,
PPARδ, PPARγ. The expression of PPARs varies markedly across different tissues, with
PPARα being highly expressed in liver, PPARδ in skeletal muscle and PPARγ in adipose tissue
[45]. PPARs are activated by long-chain polyunsaturated fatty acids and a range of lipid
derivatives, and several mitochondrial genes, particularly those involved in fatty acid
oxidation, are amongst their gene targets [46,47]. Several lipid lowering (e.g. fibrates) and anti-
diabetic drugs (e.g. thiazolidinediones) target the PPAR proteins.
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2.2.5. Yin Yang 1 (YY1)
A range of mitochondrial genes are also regulated by the transcription factor YY1. Puigserver’s
group have shown that the regulation of mitochondrial oxidative function by mTOR is
regulated through YY1 [48] and recently it has been shown that mitochondrial function and
morphology are abnormal in mice with muscle-specific YY1 knockout, highlighting an
important role for this transcription factor in regulating mitochondrial function [49].
2.3. Mitophagy
In addition to the biogenesis of new organelles, mitochondrial content is also partly determined
by the rate of degradation. Indeed, mitochondrial autophagy (or mitophagy) is now recognized
as a key quality control process regulating mitochondrial homeostasis [50]. Autophagy is a
conserved cellular event in which damaged organelles and proteins are degraded in a two-
step process, that first involves the formation of a double membrane structure called the
‘autophagosome’, followed by the fusion of the autophagosome with lysosomes and the
subsequent degradation of the enveloped contents. Mitophagy can be inititiated by a number
of events that signal stress within mitochondria, such as opening of the permeability transition
pore or fragmentation of mitochondria [51,52]. The list of proteins that are thought to be
involved in the mitophagy process (e.g. PINK1, Parkin, Nix) is increasing rapidly [50]. From
a physiological perspective, mitophagy plays important roles in several developmental
processes, such as red blood cell maturation and the removal of paternal mitochondria
following fertilization of the oocyte [53-55]. However, recent evidence also suggests that
abnormal mitophagic activity may contribute to the aging process, as well as a number of
different diseases, such as neurodegenerative disorders [56].
2.4. Intrinsic factors regulating mitochondrial function
While the number of mitochondria is obviously an important determinant of the oxidative
capacity of different tissues, variations in the intrinsic properties of mitochondria are also
critical. Mitochondria from different sites in the body can have different capacities for the same
process. For example, mitochondria from red slow-twitch and white fast-twitch muscle display
very different rates of fatty acid oxidation [57]. This difference is in line with the functional
requirements of these muscles, and is likely related to the differences in protein expression of
key enzymes in this pathway [58]. In addition to differential expression of proteins within
specific pathways, another emerging factor that may influence mitochondrial oxidative
capacity is post-translational modifications of mitochondrial enzymes. Following translation,
many different facets of protein function (activity, subcellular localization, protein-protein
interactions) can be altered by the addition of functional groups to specific residues in the
protein. The most well-described PTM is likely phosphorylation, and proteomics screens have
revealed widespread phosphorylation of mitochondrial proteins [59]. The activity of specific
mitochondrial proteins, such as uncoupling protein 3, has been shown to be directly regulated
by phosphorylation [60]. Other recent work has shown that perhaps the most abundant PTM
in mitochondria is lysine acetylation. Acetylation involves the transfer of an acetyl group from
acetyl-CoA to a lysine residue in specific proteins. More than 30% of mitochondrial proteins
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have been shown to be acetylated, and reversible lysine acetylation/deacetylation has been
shown to impact on the activity of a large range of mitochondrial enzymes involved in virtually
all metabolic pathways within this organelle [61]. In addition to phosphorylation and acety‐
lation, numerous other PTMs (e.g. glutathionylation, nitrosylation, succinylation) have been
described as being present in mitochondria [62-64], and their functional importance remains
to be determined.
2.5. Mitochondrial dynamics
Mitochondria are not static organelles, but exist largely as a reticular network. Mitochondria
are constantly engaged in the process of fusion and fission, providing morphological plasticity
to allow adjustments in response to the prevailing cellular stresses and metabolic requirements
[65]. Mitochondrial fusion is mediated by the mammalian GTPases mitofusin 1 and mitofusin
2, as well as optic atrophy protein 1 (Opa1). Fusion occurs in a two-step process, which initially
involves fusion of the outer membrane (mediated by mitofusins), followed by subsequent
fusion of the inner membrane (driven by Opa1) [66,67]. Fission is regulated by another GTPase,
dynamin-related protein 1 (Drp1), which resides in the cytosol and is recruited to the mito‐
chondrial surface to engage other key components of the fission machinery (e.g. Fis 1) [68,69].
The fusion process is thought to allow two mitochondria to functionally complement each
other through the exchange and repartitioning of their respective components (e.g. copies of
the genome, metabolic enzymes and metabolites). Fission on the other hand is important both
in the separation of the organelle into daughter cells during cell division and also in isolating
and targeting damaged mitochondria for degradation. Collectively the balance of fusion and
fission allows mitochondria to form a spectrum of shapes from small individual units to
elongated interconnected networks.
In muscle cells, the mitochondrial network is arranged into two discrete, but interconnected
pools – the subsarcolemmal (SS) pool near the cell surface, and the intermyofibrillar (IMF) pool
in the interior of the cell between myofibres [70-72]. These two pools of mitochondria have
been reported to display some differences in their metabolic characteristics, with SS mito‐
chondria appearing to be more responsive to increase their oxidative capacity following an
exercise stimuli than IMF mitochondria [57,73]. Despite the differences between mitochondrial
pools, it has been proposed that the arrangement of mitochondria may important for efficient
mitochondrial function; SS mitochondria have greater access to oxygen and metabolic
substrates, and the proton gradient generated through substrate oxidation in the SS pool may
potentially contribute fuel ATP synthesis in the IMF pool, where energy demands are highest
during contraction [71].
3. Mitochondrial dysfunction in muscle and its association with insulin
resistance
As detailed above, mitochondria represent complex organelles and perturbations in any aspect
of mitochondrial regulation and function, could impact on metabolic homeostasis. The
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mitochondrial theory of insulin resistance has developed over the last 10-15 years and is based
on the notion that defective mitochondrial metabolism will result in inadequate substrate
oxidation, leading to a buildup of lipid metabolites and the subsequent development of insulin
resistance. Support for this theory comes from many studies in humans and rodents, which
have largely examined skeletal muscle and are reviewed below.
In the late 1990’s and early part of last decade, several groups published studies showing that
muscle from obese and insulin resistant subjects displayed reduced oxidative enzyme activity
[74-76]. Some of these studies also examined lipid oxidation either in muscle homogenates, or
by making RQ measurements across the leg, and it was shown that fatty acid oxidation was
also decreased in obese, insulin resistant subjects compared to age-matched controls, poten‐
tially suggesting that defects in mitochondrial metabolism may be involved in the develop‐
ment of obesity and insulin resistance [74,75]. In 2002, Kelley’s group showed that there was
lower NADH:O2 oxidoreductase activity and reduced mitochondrial size, as determined by
electron microscopy, in muscle of obese subjects with insulin resistance and/or T2D compared
to controls [77]. A year later, two influential microarray studies were published, reporting a
coordinated downregulation of genes involved in mitochondrial biogenesis and oxidative
phosphorylation in subjects with T2D and non-diabetic individuals with a family history (FH
+) of T2D [78,79]. These microarray studies were considered particularly important, as they
documented a reduction in the master regulator of mitochondrial biogenesis, PGC-1α, and
thus they provided a mechanism for the reduced oxidative gene expression. They were also
important, as they showed that abnormal mitochondrial gene expression could be observed
in insulin resistant relatives of patients with T2D and thus may be a pathogenic factor in the
‘pre-diabetic’ state. Overall the conclusion from these studies was that depressed PGC-1α
levels, due to genetic predisposition, physical inactivity, or excessive caloric intake, could lead
to a reduction in mitochondrial content, predisposing individuals to develop insulin resistance
and T2D.
In the ensuing decade since these landmark studies were published, there has been intense
research into this field and one issue that has arisen is how to best measure mitochondrial
function/dysfunction. Numerous approaches have been employed, including measurements
of parameters in frozen muscle samples (e.g. mRNA, protein content, oxidative enzyme
activity and mtDNA), functional assessment of substrate oxidation in fresh samples (e.g.
radiolabelled fatty acid oxidation, mitochondrial respiration measurements) and non-invasive
magnetic resonance spectroscopy (MRS) with 31P or 13C to determine in vivo ATP synthesis
rates, phosphocreatine resynthesis rates or TCA cycle activity as an index of mitochondrial
function. All these assays provide some indication of mitochondrial function, however they
may not always correlate with each other and this needs to be considered when interpreting
studies in this area. Details of a number of key studies in this area are presented in the following
sections.
In line with the microarray studies noted above, mRNA levels for a variety of mitochondrial
genes have been shown to be reduced in muscle biopsies obtained from various insulin
resistant populations, including lean insulin-resistant offspring of patients with T2D [80],
obese subjects [81], patients with polycystic ovarian syndrome [82] and subjects with estab‐
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lished T2DM [83,84]. The level of mtDNA was also shown to be lower in both obese, insulin
resistant subjects and obese subjects with T2D [85,86]. Heilbronn et al. [81] demonstrated
reduced protein expression of respiratory chain subunits in obese insulin-resistant subjects
and consistent with these findings, a recent proteomics study comparing lean, obese and T2D
subjects, showed patterns of reduced mitochondrial proteins in the insulin-resistant subjects
[87]. The activity of specific enzymes involved in oxidative pathways have been reported to
be lower in various insulin-resistant populations [81,86,88,89] and additionally electron
microscopy studies have reported reduced mitochondrial size and density in insulin-resistant
muscle [77,80,86]. Interestingly, in the studies reporting mitochondrial deficiencies, there has
been disparate results regarding which population of mitochondria may underlie the func‐
tional defects. Ritov et al. [86] reported that the number and functional activity of subsarco‐
lemmal mitochondria was reduced in obesity and T2D, while a more recent study found similar
subsarcolemmel mitochondrial content in lean controls, lean insulin-resistant non-diabetic
subjects and insulin-resistant T2D subjects, however intermyofibrillar mitochondrial content
was reduced in the latter two groups [90]. Differences in mitochondrial function may not only
be present within different intramuscular populations, but also between different muscles
across the body. Rabol and colleagues used high resolution respirometry to measure mito‐
chondrial function in saponin-permeabilised fibres from m. deltoideus and m. vastus lateralis
and observed reduced respiratory capacity only in the leg muscles of type 2 diabetic subjects
compared to lean controls [91].
In addition to the above studies, several investigators have also measured in vivo mitochondrial
function using MRS. Petersen et al. [92] studied lean, healthy elderly subjects using hyperin‐
sulinemic-euglycemic clamps and MRS measurements and observed marked insulin resist‐
ance in skeletal muscle of the elderly subjects compared to weight-matched controls. This
impairment in insulin action was associated with a 40% reduction in ATP synthesis capacity,
and a pronounced accumulation of intramuscular fat. The same group published a paper the
following year in which they studied lean insulin-resistant offspring of patients with T2D using
the same methods. The insulin-resistant offspring displayed a 60% reduction in insulin-
stimulated glucose uptake into muscle and this was again associated with increased intra‐
myocellular lipid and reduced basal mitochondrial ATP synthesis capacity [93]. A subsequent
study by Petersen et al. [94] also reported reduced-insulin-stimulated ATP synthesis in first-
degree relatives of subjects with T2D and in later work it was shown that family history of T2D
was associated with reduced TCA cycle flux [95]. In several other studies, patients with T2D
have been shown to have reduced ATP synthesis capacity or phosphocreatine recovery rates,
indicative of reduced mitochondrial function in these populations [96-99]. A further interesting
case report using MRS showed that a MELAS patient with mtDNA mutations, displayed
insulin resistance in muscle association with reduced baseline and insulin-stimulated ATP
synthesis capacity [100].
A number of investigations have sought to determine if there is an intrinsic difference in the
functional capacity per mitochondrion that may underlie the reductions in mitochondrial
function reported with MRS. Some studies examining respiration or fatty acid oxidation in
isolated mitochondria or permeabilised muscle fibres, have reported that the functional
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capacity per mitochondrion in insulin resistant and/or type 2 diabetic subjects is similar or only
very mildly reduced [85,88,91,101-103] in insulin-resistant individuals, but when normalized
to muscle mass, a substantial reduction is seen in insulin-resistant subjects [85,88,101]. These
studies therefore only see marked differences when mitochondrial capacity is expressed per
unit mass of skeletal muscle and thus indicate that in vivo mitochondrial defects observed with
MRS may be more strongly related to reductions in mitochondrial number, than to substantial
intrinsic mitochondrial defects. However, an elegant study by Phielix et al. [97] measured both
in vivo mitochondrial function (with MRS) and ex vivo mitochondrial respiration in muscle
from the same patients with T2D and they reported that in this population of subjects, the in
vivo defects in mitochondrial function could be attributed to impairments in intrinsic mito‐
chondrial substrate oxidation. Another study from this group also observed similar differences
in intrinsic mitochondrial function in T2D patients compared to BMI-matched controls [96].
One limitation of the aforementioned studies is that they only provide static measurements of
different populations at a given time and are unable to delineate whether the observed defects
in mitochondrial metabolism are primary drivers of insulin resistance or arise as a consequence
of decreases in insulin action. In this regard, intervention studies in rodents and humans have
provided some experimental evidence that manipulations which result in declines in insulin
action, are also associated with mitochondrial dysfunction. For example, infusion of fatty acids
into humans for 6–48h to mimic the effects of chronic lipid overload resulted in a robust
induction of whole-body insulin resistance and reduced insulin-stimulated ATP synthesis
rates and expression of mRNA encoding PGC1α and other mitochondrial genes in muscle
[104-106]. In healthy male subjects, high-fat feeding for 3 days was sufficient to reduce mRNA
levels of PGC1α, PGC-1β and several other mitochondrial genes in skeletal muscle [107].
Similarly, genetic, or high-fat diet-induced obesity and insulin resistance in rodents has been
reported by several groups to reduce mitochondrial gene expression, protein expression and
mitochondrial respiration in skeletal muscle [107-111]. Providing additional evidence of a link
between mitochondrial dysfunction and insulin resistance is the fact that antiretroviral therapy
used to suppress human immunodeficiency virus infection causes insulin resistance in
association with mtDNA copy number [112]. Collectively, the above studies illustrate that
there are many instances where defects in mitochondrial metabolism and impairments in
insulin action occur in conjunction with each other in skeletal muscle.
4. Mitochondrial dysfunction in tissues other than muscle
4.1. Liver
The liver plays a major role in regulating glucose homeostasis, producing glucose during the
fasting state and storing glucose after the ingestion of a meal. Hepatic insulin resistance causes
impaired glycogen synthesis and reduced suppression of endogenous glucose and is closely
correlated with excess accumulation of lipid in liver. Chronic elevation of liver lipid content
is referred to as non-alcoholic liver disease (NAFLD) and this condition progresses to non-
alcoholic steatohepatitis (NASH) when inflammatory and fibrotic processes become involved.
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A range of different parameters have been studied in rodents and humans with respect to liver
mitochondrial metabolism. The collective findings indicate that the liver appears to be able to
adapt to an excess of lipid by upregulating fatty acid oxidative capacity and TCA cycle activity,
but this is not always coupled to a concomitant increase in electron transport chain activity,
and as a consequence reactive oxygen species are produced (see [113] for an excellent review
on the topic). There are also some in vivo MRS studies that have examined indices of mito‐
chondrial metabolism in individuals with NAFLD and T2D, with the findings generally
indicating mild abnormalities in mitochondrial function in these populations [114-116].
4.2. Adipose tissue
4.2.1. White adipose tissue
White adipose tissue (WAT) serves a principal role as the most important energy store in the
body. However it has become increasingly clear over the last decade that WAT is also an active
endocrine organ, releasing adipokines that influence whole-body energy homeostasis and
insulin action. Mitochondrial content in WAT is low compared to other tissues, however the
diversity of mitochondrial proteins in WAT has been shown to be greater than in muscle and
heart [117]. Intact mitochondrial metabolism is critical for maintaining normal WAT functions,
such as the appropriate synthesis and secretion of adipokines and cycling reactions involved
in lipid synthesis [118].
WAT mitochondrial content has been reported to be reduced in insulin-resistant humans and
rodents. In women with T2D, electron transport chain genes were shown to be downregulated
in visceral WAT independently of obesity and perhaps as a consequence of TNFalpha-induced
inflammation [119]. In obese humans, mtDNA copy number was reported to be lower than in
control subjects and was directly correlated with basal and insulin-stimulated lipogenesis
[120]. In rodent models of genetic or dietary-induced obesity and insulin resistance, there are
reductions in mtDNA copy number, mitochondrial density and mitochondrial OXPHOS
activity [121-123]. Administration of thiazolidinediones promotes mitochondrial biogenesis in
WAT in animals and humans, in conjunction with improved whole-body insulin sensitivity
[46,123], suggesting that specific changes in WAT mitochondrial metabolism in obesity and
T2D, may be imparting whole-body metabolic consequences. Indeed, recent work has shown
adipose-restricted alterations in mitochondrial activity can have profound effects on global
glucose and lipid homeostasis [124,125].
4.2.2. Brown adipose tissue
Unlike WAT, the principal function of brown adipose tissue (BAT) is energy dissipation, rather
than energy storage. BAT has a high mitochondrial density per gram of tissue, and the unique
presence of uncoupling protein 1 (UCP1) allows brown adipocytes to couple the oxidation of
lipids, not to ATP synthesis, but to heat generation via proton leak across the mitochondrial
inner membrane. Interest in brown adipose tissue has recently soared on the back of 3
important papers published in 2009 that unequivocally demonstrated the presence of func‐
tional BAT in humans [126-128]. There is an inverse correlation between BAT activity (as
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assessed by fluorodeoxyglucose PET) and obesity, suggesting that individuals with low BAT
mitochondrial activity, may be prone to obesity and other metabolic diseases [126,127,129-131].
4.3. Heart
Like skeletal muscle, translocation of GLUT4 in response to insulin occurs in myocardium.
This process is blunted in insulin-resistant humans and animals in association with other
abnormalities in fuel metabolism ([132-134]. With respect to mitochondrial metabolism,
genetic and diet-induced obesity and type 2 diabetes in rodents is associated impaired
mitochondrial function [135-137]. MRS studies in individuals with T1DM, T2DM, obesity and/
or NAFLD have also reported that that there is a decreased ratio of phosphocreatine:ATP in
myocardium, potentially indicating derangements in mitochondrial substrate metabolism in
these populations [138-142].
5. What factors lead to mitochondrial dysfunction in insulin resistance?
As noted in the previous section, mitochondrial dysfunction is frequently documented in
insulin resistant states and there are many possible factors that may underlie this relationship.
5.1. Insulin resistance
Insulin is a potent anabolic hormone and it has been proposed that mitochondrial dysfunction
may emerge secondary to insulin resistance. Insulin infusion in humans leads to increases in
mitochondrial gene expression, higher oxidative enzyme activity and elevated ATP synthesis
in muscle [143,144]. This response is attenuated in insulin-resistant T2D individuals, support‐
ing a direct role for insulin resistance leading to mitochondrial dysfunction [143]. Further
evidence for this notion comes from a study by Karakelides et al, who showed that acute insulin
removal from subjects with type 1 diabetes, caused reductions in mitochondrial ATP produc‐
tion and in mitochondrial gene expression in skeletal muscle [145]. Additionally a recent study
in patients with congenital defects in insulin signal transduction, reported that mitochondrial
function (assessed by phosphocreatine recovery rates) in muscle was reduced in this popula‐
tion [146]. Finally a recent study that induced insulin resistance by prolonged fasting, also
reported defects in mitochondrial function [147]. Overall these studies indicate that insulin can
directly regulate mitochondrial biogenesis and metabolism, and therefore it is plausible that
some of the mitochondrial defects observed in insulin-resistant subjects, could be a conse‐
quence of the insulin resistance itself.
5.2. Altered mitochondrial dynamics
Any perturbation in the dynamics of the mitochondrial network could potentially contribute
to the pathogenesis of insulin resistance in skeletal muscle. The complex process of mitochon‐
drial fission and fusion has been described above and alterations in key proteins mediating
these dynamic events have been reported in insulin resistant and obese states. The expression
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of mitofusin 2 (MFN2), which appears to have additional pleitropic effects in cells beyond the
maintenance of the mitochondrial network [148-152], is reduced in the skeletal muscle of obese
insulin-resistant humans, type 2 diabetic humans and diabetic Zucker rats [149,153] and
correlates with the capacity for glucose oxidation [154]. Repression of MFN2 in L6E9 muscle
cells and 10T/2 fibroblasts results in decreased glucose oxidation, cellular respiration, mito‐
chondrial membrane potential, and causes fragmentation of the mitochondrial network [149]
and liver-specific deletion of MFN2 results in glucose intolerance and impairments in insulin
signaling [155]. Recent work has also shown that mice deficient in the mitochondrial protease
OMA1, display obesity and altered metabolic homeostasis, due to altered processing of the
inner membrane fusion protein OPA1 and disruptions in mitochondrial morphology and fuel
metabolism [156]. It has also been reported that abnormalitieis in mitochondrial fission events
may play a role lipid-induced insulin resistance. In C2C12 muscle cells, palmitic acid (but not
other long-chain fatty acids) was shown to induce mitochondrial fragmentation in conjunction
with insulin resistance and this effect could be blocked by genetic or pharmacological inhibi‐
tion of Drp1 [157]. Analysis of tissues from ob/ob mice and high-fat fed mice in this study
revealed increased Drp1 and Fis1 levels and pre-treatment of ob/ob mice with the Drp1 inhibitor
Mdivi-1 resulted in a mild improvement in insulin action in these animals. Collectively these
studies suggest that alterations in the equilibrium of mitochondrial fission and fusions events
may play some role in the pathogenesis of insulin resistance.
5.3. Reduced physical activity
Physical inactivity has recently been reported to be as big a risk factor for non-communicable
diseases as smoking, stressing the importance of exercise in metabolic health [158]. Exercise is
one of the major stimuli for mitochondrial biogenesis and chronic inactivity results in decreases
in mitochondrial number in muscle [159]. A number of studies have shown that obesity and
other metabolic disorders are characterised by decreased physical activity levels and elevations
in sedentary behaviour [160-162]. Interestingly the sedentary behaviours (e.g. sitting time) do
not seem to be influenced by changes in weight and have been suggested to be biologically
determined [161]. Given these differences, it is likely that some of the mitochondrial defects
reported in overweight or obese insulin-resistant subjects may be explained, in part, by low
levels of physical activity.
5.4. Genetic and epigenetic factors
There is evidence in the literature that the metabolic phenotype of skeletal muscle may be
strongly influenced by genetic programming. For example, despite being cultured under
similar conditions for several weeks, studies have shown that primary human skeletal muscle
cells in culture display a similar metabolic phenotype (e.g. gene expression and lipid parti‐
tioning) to that of the donor subject from which they originated [163,164]. Mutations in nuclear-
encoded genes involved in mitochondrial function (e.g. PGC-1α, NDUFB6) have been linked
with insulin action and T2D, as have mtDNA deletions [165,166]. An emerging area of research
is also the regulation of mitochondrial function by epigenetic factors. Barres et al showed that
the promoter of PGC-1a is methylated at non-CpG sites and exposure of primary human
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myotubes to hyperlipidemia or inflammatory stimuli, promoted PGC-1α hypermethylation.
Intriguingly PGC-1α hypermethylation was observed in muscle of T2D patients in conjunction
with reduced mitochondrial density [167]. PGC-1α hypermethylation has also been linked
with insulin resistance in non-alcoholic fatty liver disease [168]. A number of other studies
have also reported that methylation of other mitochondrial genes (e.g. NDUFB6 and ATP50)
as well as TFAM, can be regulated by methylation and associated with insulin resistance.
[166,168-170]. One recent study has also shown that methylation of mitochondrial DNA is also
correlated with severity of NAFLD [171]. In addition to methylation, acetylation can also
influence gene transcription and the potential importance of this epigenetic factor is high‐
lighted by a recent study showing that pharmacological inhibition of HDAC1 in cells and obese
animals could promote mitochondrial biogenesis and improve metabolic phenotype [172].
Overall the above studies indicate that specific chromatin modifications may influence
mitochondrial function in insulin resistance and T2D.
5.5. Oxidative stress
Oxidative stress can be defined as a chronic imbalance between the production of reactive
species and the protection against these species by antioxidant defenses, ultimately leading to
macromolecular damage. Reactive oxygen species (ROS) are an unavoidable byproduct of
metabolic reactions within cells and a major site for ROS production is the mitochondrion
[173]. Studies from a number of different groups have shown that in genetic or diet-induced
obese rodents, there is increase ROS production [4,5,174,175]. Importantly, most [4,5,175,176],
but not all studies [177] show that insulin action is improved by genetic or pharmacological
attenuatation of mitochondrial ROS production, indicating an especially important role for
generation of reactive species in this organelle. Since mitochondria are particularly susceptible
to oxidative attack [178,179], it is possible that overactive ROS generation in response to obesity
or high dietary lipid supply, may lead to defects in mitochondrial function. Indeed, Bonnard
et al. fed mice a long-term diet rich in fat and sugar and concluded that under their specific
experimental conditions, oxidative stress was involved in the induction of mitochondrial
dysfunction [108].
5.6. Post-translational regulation of mitochondrial function
As noted above, there is an emerging appreciation for the fact that specific mitochondrial
enzymes and pathways may be regulated by post-translational modifications. Several groups
have shown that mitochondrial acetylation is increased in tissues of diet-induced obese mice
[180,181]. SIRT3 is a key regulator of mitochondrial acetylation and the expression of this
deacetylase enzyme is markedly reduced in a number of different experimental models of
insulin resistance and diabetes [181-183]. SIRT3 KO mice display insulin resistance in muscle
[182] and these mice also exhibit an accelerated development of the metabolic syndrome when
challenged with long-term high fat diet, in association with pronounced hyperacetylation of
liver mitochondria [181]. Interestingly, in addition to showing that SIRT3 KO mice have a
compromised phenotype, Hirschey et al have also shown that a point mutation in SIRT3 that
results in reduced activity of this protein, is associated with the development of metabolic
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syndrome in humans [181]. The above studies suggest that altered acetylation of mitochondrial
proteins may associate with insulin resistance and impaired mitochondrial function, and while
further study in this field is required, there is some evidence that other mitochondrial PTMs
may also be altered in insulin resistance and T2D [184,185].
6. Mitochondrial dysfunction is not always linked with insulin resistance
Despite the frequent association of mitochondrial dysfunction and insulin resistance, evidence
of a cause-and-effect relationship between the two is still lacking. In fact, a substantial literature
now exists in both humans and rodents directly challenging the notion that deficiencies in
mitochondrial oxidative capacity are an obligate part of the link between lipid accumulation
(obesity) and insulin resistance.
6.1. Human studies
Trenell and colleagues used MRS to determine basal and maximal ATP turnover in muscle of
well-controlled T2D patients compared with physical activity-, age- and weight-matched
control subjects and observed no difference between the two groups [186]. A similar finding
was reported in a separate population where post-exercise phosphocreatine recovery indicated
similar mitochondrial function between obese patients in either the early or advanced stages
of T2D and normoglycemic controls matched for age, body composition and habitual physical
activity levels [187]. A further study from the same group also recently reported similar in
vivo mitochondrial function with MRS in prediabetic subjects compared with age, BMI and
activity-matched controls, despite the presence of insulin resistance (by HOMA-IR and OGTT)
[83]. In young lean men born with low birth-weight, mitochondrial function by MRS and
mitochondrial gene expression are intact, despite these subjects displaying several pre-diabetic
characteristics [188]. Two groups have also reported measurement of in vitro ATP production
capacity and respiratory charactersitics in mitochondria isolated from obese subjects and fail
to see any difference compared to controls [189,190]. Studies in different ethnic groups have
also provided data contrary to the mitochondrial dysfunction theory of insulin resistance. Nair
et al. showed that despite being more insulin resistant than age, sex and BMI-matched North
American subjects, Asian Indians exhibit higher mtDNA content, elevated expression of genes
involved in oxidative phosphorylation, increased oxidative enzyme activity and greater
mitochondrial ATP production rates in muscle [191]. In this study the authors also went on to
stratify the Asian Indian group into those with T2D and those without, and despite the diabetic
individuals displaying impaired insulin sensitivity and increased muscle lipid levels, there
was no difference in the various markers of mitochondrial oxidative capacity.
The studies above provide evidence that at least in those populations, mitochondrial dysfunc‐
tion does not seem to be present in a number of insulin resistant groups. In line with these
examples of a discordant relationship between these two variables, several human intervention
studies have also shown that changes in insulin sensitivity can occur without concurrent
improvements in mitochondrial function. For instance, dietary restriction in overweight and
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obese subjects enhanced insulin sensitivity, without altering mtDNA, cardiolipin content or
NADH-oxidase activity [192]. Improved insulin sensitivity was reported in insulin-resistant
subjects with a family history of T2D following 7 days of treatment with the anti-lipolytic agent
acipimox, yet mitochondrial gene expression in muscle actually declined in these subjects
[193]. Treatment of diabetic patients with rosiglitazone improved insulin sensitivity, without
altering in vivo mitochondrial function or markers of mitochondrial content [194,195]. Recently
Samocha-Bonet also showed that 28 days of high-fat overfeeding was sufficient to induce
insulin resistance in health humans, without any detectable defects in various markers of
mitochondrial function [6]. Shorter-term overfeeding studies in low birth-weight subjects also
revealed a disconnect between the induction of insulin resistance and the response of mito‐
chondrial metabolism [196].
6.2. Rodent studies
To complement the studies in humans, a number of investigators have used gene-manipu‐
lated mice to more directly test whether specifically targeting mitochondrial metabolism,
can induce changes in insulin sensitivity. Mitochondrial oxidative capacity was shown to
be compromised in muscle-specific TFAM knockout mice, however these animals exhibit‐
ed  improved glucose  clearance  during  a  glucose  tolerance  test  and  maintained  insulin-
stimulated glucose uptake in muscle [197]. TFAM knockout in adipose tissue was recently
shown  to  protect  against  diet-induced  obesity  and  insulin  resistance,  despite  causing
abnormalities in mitochondrial function [125]. Similar findings were reported in mice with
liver  or  muscle-specific  deletion of  apoptosis-inducing factor.  These  animals  exhibited a
gene expression pattern of mitochondrial oxidative phosphorylation deficiency similar to
that  observed in  human insulin  resistance [78,79],  however  they were  lean and insulin-
sensitive and did not manifest the usual deleterious effects of a high-fat diet [198]. A number
of groups have also targeted other regulators of mitochondrial  function in mice.  Due to
their key role in mitochondrial biogenesis, muscle-specific knockout of PGC-1α or loss-of-
function mutation of PGC-1β produced the expected decline in markers of mitochondrial
function yet insulin sensitivity in muscle was preserved or in fact slightly enhanced in these
animals  compared to  wild-type counterparts  [26,199].  Two separately  generated lines  of
muscle-specific  PGC-1α  transgenic  mice  have  shown  predictable  increases  in  many
mitochondrial  parameters,  but  these  animals  are  insulin  resistant,  potentially  due  to
excessive fatty  acid delivery into muscle  [200]  or  decreased GLUT4 expression [201].  In
other  examples  of  a  dissociation between insulin  resistance  and mitochondrial  dysfunc‐
tion, it has been shown that Zucker diabetic fatty (ZDF) rats display normal in vivo muscle
oxidative capacity and improved activity of enzymes involved in lipid oxidation during the
progressions to insulin resistance and T2D [202], while db/db mice and ob/ob mice have been
shown to exhibit higher mitochondrial oxidative capacity in liver compared to lean control
animals [203,204]. Collectively the above studies clearly demonstrate that targeted manipu‐
lation of mitochondrial function, does not produce ‘predictable’ alterations in insulin action.
A caveat to these studies is that in genetically manipulated mice, there is a complete lack
or substantial increase in the content/function of a specific protein and thus caution must
be  exercise  when  interpreting  the  findings,  as  the  phenotype  (or  lack  thereof)  may  be
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partially related to other compensatory adaptations (e.g. activation of AMP-activated protein
kinase or increase in some other lipid metabolism pathway) induced by the alterations in
specific genes [197,200].
Dietary studies are another robust approach to test whether mitochondrial defects can be
causally linked with changes in insulin action. Feeding rats an iron-deficient diet causes a
deficiency in mitochondrial electron transport chain enzymes, however this is not associat‐
ed with the development of insulin resistance [205]. In 2007, our group showed that high-
fat feeding in mice induced insulin resistance and was associated with increased expression
of a PGC-1α and a number of mitochondrial proteins, elevated oxidative enzyme activity
and higher fatty acid oxidation rates [206]. Furthermore we also demonstrated that similar
changes in markers of mitochondrial metabolism were present in muscle from high-fat fed
rats, db/db mice and fa/fa Zucker rats. These findings of enhanced mitochondrial oxidative
capacity occurring in parallel with the induction of insulin resistance, suggested that diet-
induced insulin resistance does not involve mitochondrial dysfunction. At a similar time
Garcia-Roves also showed that high-fat feeding with daily heparin injections in rats resulted
in mitochondrial biogenesis in skeletal muscle [207] and subsequent work by the same lab
the  following  year  confirmed  that  oversupply  of  dietary  lipid  produced  insulin  resist‐
ance, despite an increase in mitochondria in muscle [208]. Since the time of these publica‐
tions, a number of other groups have shown that diets rich in fat increase mitochondrial
biogenesis in muscle, despite the fact that the same diets robustly induce whole-body and
muscle-specific  insulin  resistance  [209-211].  One  interpretation  of  these  findings  is  that
skeletal  muscle  is  mounting an appropriate  response  to  the  increase  in  caloric  load,  by
upregulating catabolic pathways, however this response is inadequate or mismatched with
the elevation in nutrient intake, thus resulting in ectopic lipid accumulation in muscle and
insulin  resistance.  Interestingly  we  have  shown  that  the  upregulation  of  mitochondrial
oxidative capacity is far greater when medium chain fatty acids are substituted for long
chain fatty acids in the diet and this is sufficient to prevent the accumulation of myocellu‐
lar lipid and the development of insulin resistance in muscle [212]. Enhancing mitochondri‐
al  metabolism acutely  by  genetic  means  in  muscle,  also  seems to  be  sufficient  to  boost
mitochondrial fuel oxidation to the point where insulin resistance is ameliorated in muscle
in fat-fed animals [25,213].
One interesting observation to come out of the dietary studies in rodents is that from Muoio’s
group. They reported that the increased mitochondrial fatty acid oxidation that occurs in
response to high-fat feeding, results in the generation of acylcarnitines as incomplete oxidation
products [214]. This acylcarnitine signature, which is thought to disturb the mitochondrial
CoA equilibrium and indicate a state of mitochondrial stress, has also been observed in humans
with obesity and T2D [215,216]. Whether the acylcarnitines can directly contribute to the
development of insulin resistance is currently unclear, but recent work suggests that these
metabolites serve as a marker for the inability of mitochondria to efficiently transition between
fuel substrates [217].
In summary, while there are a large number of studies that document an association between
mitochondrial dysfunction and insulin resistance in lean and obese subjects, there is now a
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significant literature showing that alterations in mitochondrial function in muscle and insulin
action are not always correlated. There are a myriad of differences between studies that may
explain these discrepancies, including the particular population of individuals studied and
their ethnic background and physical fitness level, the muscle group examined, the dietary
regime employed in rodent and human studies (e.g. duration of feeding, fat content and
composition) and the particular assay/technique used to assess mitochondrial function.
7. Are mitochondria good therapeutic targets for the treatment of insulin
resistance and T2D?
While the precise role of mitochondria as pathogenic drivers of insulin resistance and T2D
remains controversial, it should be recognized that even if mitochondrial defects arise
secondary to the development of insulin resistance or as a consequence of obesity, reductions
in oxidative fuel metabolism are likely to accelerate ectopic lipid deposition in non-adipose
tissues and thereby exacerbate the insulin-resistant state. Therefore it would appear that
stimulating mitochondrial biogenesis and fuel metabolism, could have beneficial effects for
treating metabolic diseases. Evidence in this regard is summarised below
7.1. Exercise
Exercise  robustly  stimulates  mitochondrial  biogenesis  in  muscle  and has  a  multitude of
health benefits, including improving insulin action. An 8 week cycling regime in sedenta‐
ry  elderly  subjects  increased  muscle  fatty  acid  oxidative  capacity  and  in  parallel  im‐
proved  insulin-mediated  glucose  disposal  [218].  A  ten  week  exercise  training  program
produced similar improvements in insulin sensitivity and muscle oxidative enzyme activity
in both first degree relatives of T2D patients compared with age-, sex- and BMI-matched
controls  [219].  Toledo  reported  that  4  months  of  exercise  training  in  T2D  patients  in‐
creased  skeletal  muscle  mitochondrial  density,  cardiolipin  content  and  mitochondrial
oxidation enzymes,  in  conjunction with  a  60% improvement  in  insulin  sensitivity  [220].
Aerobic cycling training for 10 weeks in obese, T2D male subjects induced an ~20% increase
in insulin sensitivity and a 40% increase in mitochondrial content, with these changes of a
similar  magnitude to  that  observed in  matched control  subjects  [221].  Twelve  weeks  of
combined progressive training was also sufficient to overcome the in vivo  mitochondrial
impairment  observed  in  a  group  of  T2D  patients,  with  a  concomitant  improvement  in
insulin sensitivity also observed [96]
7.2. Caloric restriction and modulation of sirtuin enzymes
Caloric restriction has been shown to improve insulin sensitivity in humans [222,223] and to
improve markers of mitochondrial function in muscle of humans and rodents [224,225]. Many
of the beneficial effects of calorie restriction have been proposed to be through stimulation of
the SIRT1 pathway. Indeed studies have shown that activators of SIRT1 (e.g. resveratrol and
more potent specific activators) can enhance mitochondrial metabolism and improve insulin
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action in rodent models of insulin resistance and T2D [226-229]. Recently it was also shown
that 30 days of resveratrol supplementation improved some markers of mitochondrial function
in muscle of obese subjects, in parallel with improved HOMA-IR and reduced hepatic lipid
levels [230]. These effects seem to be limited to metabolically compromised subjects, as
resveratrol did not improve markers of glycaemic control in non-obese women with normal
glucose tolerance [231]. An alternative approach to using direct SIRT1 activators to mimic
calorie restriction, is to increase the intracellular levels of NAD+, the obligate co-factor for the
sirtuin reaction. Indeed two recent studies using different NAD+ precursors, nicotinamide
mononucleotide or nicotinamide riboside, have both reported beneficial metabolic effects on
metabolic homeostasis in animals models of insulin resistance and T2D [232,233].
7.3. Mitochondrial uncoupling
As noted above, energy dissipation or wasting can occur in a process known as mitochondrial
uncoupling. While this occurs naturally through uncoupling proteins, there are also a phar‐
macological agents that can induce mitochondrial uncoupling, such as DNP (2,4-dintirophe‐
nol). These uncoupling agents are generally lipophilic weak acids, that cause mitochondrial
uncoupling by transporting protons across the mitochondrial inner membrane into the matrix,
deprotonating and then exiting as anions before repeating the catalytic cycle. Uncoupling
agents have been successfully used in the past as obesity treatments. In the 1930’s DNP was
shown to be an effective weight-loss drug in humans, providing an important proof-of-concept
that the stimulation of energy expenditure by uncoupling is not necessarily compensated for
by an increase in caloric intake [234]. Despite its success as an anti-obesity therapy, DNP was
withdrawn from the market in 1938 as it (like most uncouplers) has a narrow therapeutic
window, with overdoses causing serious complications (even death) by compromising cellular
energy homeostasis. Due to the current obesity epidemic, and illicit sales via the internet, it is
alarming to see that DNP has made a comeback as a weight loss agent, with predictable lethal
results [235,236]. Thus, while mitochondrial uncoupling with DNP does not appears to be a
safe weight-loss therapy, other more recently described uncoupling agents may potentially
have a safer profile for use in humans [237-239]. An additional approach may to be to upre‐
gulate physiological uncoupling in brown adipose tissue, via sympathomimetic agents or
agonists for thyroid hormone or bile acid receptors.
7.4. Natural compounds
Natural compounds are another rich source of potential therapeutics for obesity and type
diabetes, as there is often a long history of use of these compounds in the treatment of metabolic
diseases states. One such compound is berberine, a natural plant alkaloid that has been used
as a traditional medicine in many Asian countries. Berberine was shown to improve insulin
sensitivity in a range of animal models [240] and there is also evidence of beneficial effects in
humans [241]. Although enhancing mitochondrial function appears to be an effective treat‐
ment for insulin resistance, we showed that berberine acted through inhibition of Complex 1
of the electron transport chain [242]. This mild mitochondrial inhibition led to the activation
of AMPK and subsequent metabolic benefits. Interestingly this pattern of mild inhibition of
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mitochondrial metabolism has been reported in other insulin-sensitising medicinal plants
[243] and is also a characteristic of metformin and thiazolidinediones, which are frontline anti-
diabetic therapies [242,244,245].
8. Concluding remarks
The mitochondrial dysfunction theory of insulin resistance, proposes that defects in mito‐
chondrial metabolism are key events involved in the pathogenesis of insulin resistance. At
present, the available literature does not provide strong evidence for this relationship, and
there is mounting evidence that mitochondrial defects observed in insulin-resistant individ‐
uals are likely acquired (e.g. due to low physical activity or caloric excess), or develop
secondary to the insulin resistance itself. Furthermore, with respect to muscle, another
important issue that needs to be considered is whether the ~30% reduction in mitochondrial
function that has been observed in some insulin-resistant humans would limit the oxidation
of fatty acids, leading to lipid accumulation as proposed [16]. At rest the rate of oxygen
utilization in muscle is low; and the fact that muscle has enormous capacity to increase
substrate oxidation over normal levels, means that there is substantial ‘spare’ capacity in this
system to maintain fatty acid utilization under normal free-living conditions when energy
requirements are low. Despite the unanswered questions about the precise role that mito‐
chondria play in insulin resistance and T2D, therapies targeting this important organelle,
should be explored for the the treatment of insulin resistance and its associated metabolic
disorders.
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